CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Targeting insulin-like growth factor-1 to treat Alzheimer's disease
Authors
Ignacio Torres Alemán
Publication date
1 August 2017
Publisher
'Informa Healthcare'
Doi
Cite
Abstract
The 'amyloid cascade hypothesis' proposes that disturbances in amyloid metabolism cause Alzheimer's disease (AD). However, a comprehensive explanation of the mechanisms leading to brain amyloidosis is still pending. Building on previous findings with insulin, and recent observations with insulin-like growth factor-1 (IGF-1) in AD pathology, new evidence suggests that the interaction of environmental factors and inheritance lead to abnormally reduced input/traffic of serum IGF-1 at the blood-brain barriers. The resultant deterioration in brain IGF-1 function may originate all the pathological changes observed in late-onset AD. These include cognitive loss, abnormal amyloid metabolism and aberrant Tau phosphorylation, as well as disturbances, such as inflammation, oxidative stress or mitochondrial dysfunction, among others. A better understanding of the role of IGF-1 in all these perturbations is required, particularly in relation to cognition. Furthermore, insight into the environmental factors contributing to abnormally reduced IGF-1 function in AD brains may become crucial in development of much needed disease-modifying strategies. © 2007 Informa UK Ltd.Peer Reviewe
Similar works
Full text
Available Versions
Digital.CSIC
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:digital.csic.es:10261/1537...
Last time updated on 13/08/2017